Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151825 (bone pain)
 3,118 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 39-year-old female underwent mastectomy for breast cancer in December 1995. However, two years later, she relapsed with multiple bone metastases. Only a partial response was obtained despite tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT). Disease progression with bone pain and an increasing in the level of serum NCC-ST439 occurred 5 months after APBSCT. Salvage chemotherapy with docetaxel 60 mg/m2 reduced her symptoms, and the level of serum NCC-ST439 decreased to within the normal range. Ten cycles of docetaxel administration were repeated without severe adverse reactions in an outpatient setting for 10 months. There is little information regarding treatment after relapse from APBSCT for breast cancer. Docetaxel may be an effective agent for patients in such a setting.
 ...
PMID:[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)]. 1096 99

While men with metastatic prostate cancer frequently show a good initial response to androgen ablation, few options have been available for progressive hormone-refractory prostate cancer, and survival following chemotherapy has not exceeded 9 to 12 months. The combination of prednisone and mitoxantrone has significant palliative effects on bone pain but does not extend survival. The combination of estramustine phosphate (EMP) with the taxanes paclitaxel or docetaxel produces greater than additive cytotoxicity in vivo, and phase I and II studies of taxane-based therapy demonstrate improved survival in hormone-refractory prostate cancer compared to historical controls. Docetaxel appears to have relatively high activity as a single agent and in combination with EMP. Further studies are needed to clarify the optimum dose of EMP, taking into account potential cardiovascular toxicity. Phase III studies of its combination with docetaxel are in progress.
 ...
PMID:Chemotherapy for androgen-independent prostate cancer. 1219 36

Hormone refractory prostate cancer (HRPC) causes substantial morbidity and mortality. There are increasing options for both first- and second-line therapy in the palliative treatment of patients with HRPC. Medications to control symptoms should first be optimized in patients with late-stage disease, and radiotherapy applied to dominant painful bone lesions. Docetaxel, mitoxantrone, satraplatin, and ixabepilone are active chemotherapeutic agents in the first- and/or second-line setting for patients with HRPC, and this may be true also of older drugs such as oral cyclophosphamide and vinorelbine. Radioisotopes such as strontium and samarium are useful for treatment of more generalized bone pain. Third-line hormonal maneuvers including glucocorticoids, ketoconazole, and estrogens can lead to further palliation in some patients, and there are provocative data that chemotherapy might restore hormonal sensitivity in a subset of patients.
 ...
PMID:Management of advanced prostate cancer after first-line chemotherapy. 1627 80